---
document_datetime: 2025-11-07 14:28:13
document_pages: 16
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/cabometyx-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: cabometyx-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 10.1189682
conversion_datetime: 2025-12-24 16:17:43.035426
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## CABOMETYX

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                              |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------|
| II/0040              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 19/06/2025                          | 23/07/2025                                  | SmPC and PL                      | Please refer to Scientific Discussion 'Cabometyx-H-C-4163- II-0040'. |
| IA/0039/G            | This was an application for a group of variations.                                                                             | 05/04/2024                          | n/a                                         |                                  |                                                                      |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient   |            |            |             | B.I.b.1.c -   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------|
| IB/0038 | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 27/11/2023 | n/a        |             |               |
| IB/0037 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 06/10/2023 | 19/09/2024 | SmPC and PL |               |
| II/0033 | Submission of the final report from study F-FR- 60000-001 (CASSIOPE) listed as a category 3 study in the RMP. This is a prospective, non-imposed and non-interventional study of cabozantinib tablets in adults with advanced renal cell carcinoma (RCC) following prior vascular endothelial growth factor (VEGF)-targeted therapy. The RMP version 7.0 has also been submitted.                                                                                                                                                                                                                                                                                            | 28/09/2023 | n/a        |             |               |

<div style=\"page-break-after: always\"></div>

|         | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |             |                                                                                                                                                                                                                                                                              |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0036 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                             | 27/06/2023 | n/a        |             |                                                                                                                                                                                                                                                                              |
| IB/0035 | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 19/06/2023 | 04/10/2023 | SmPC        |                                                                                                                                                                                                                                                                              |
| II/0032 | Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on Vanishing Bile Duct Syndrome (VBDS), to add embolism arterial to the list of adverse drug reactions (ADRs) with frequency Uncommon and to add vanishing bile duct syndrome to the list of adverse drug reactions (ADRs) with frequency Not known based on the cumulative review of the global safety database and literature search. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 08/06/2023 | 04/10/2023 | SmPC and PL | Based on safety data collected in the post-marketing setting, section 4.4 of the SmPC has been updated to add VBDS as a new warning and section 4.8 has been updated to add embolism arterial with frequency Uncommon and VBDS with frequency Not known to the list of ADRs. |

<div style=\"page-break-after: always\"></div>

| IA/0031/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                      | 10/01/2023   | n/a   |           |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------|
| IA/0030/G   | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process | 18/10/2022   | n/a   | of the AS |

<div style=\"page-break-after: always\"></div>

| PSUSA/10180 /202111   | Periodic Safety Update EU Single assessment - cabozantinib                                                                                                          | 21/07/2022   | 29/09/2022   | SmPC and PL   | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10180/202111.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0029               | Please refer to the Recommendations section above C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 15/09/2022   | 04/10/2023   | SmPC and PL   | SmPC sections 4.4 and 4.8 have been updated as follows: In differentiated thyroid carcinoma, dose reductions and dose interruptions occurred in 67% and 71% respectively of cabozantinib treated patients in the clinical trial (COSMIC-311). Two dose reductions were required in 33% of patients. The median time to first dose reduction was 57 days and to first dose interruption was 38.5 days. The most common serious adverse drug reactions in the DTC population (≥1% incidence) are diarrhoea, pleural effusion, pneumonia, pulmonary embolism, hypertension, anaemia, deep vein thrombosis, hypocalcemia, osteonecrosis of jaw, pain, palmar-plantar erythrodysaesthesia syndrome, vomiting and renal impairment. The most frequent adverse reactions of any grade (experienced by at least 25% of patients) in the DTC population included diarrhoea, PPES, hypertension, fatigue, decreased appetite, nausea, alanine aminotransferase increased, aspartate aminotransferase increased and hypocalcaemia. |

<div style=\"page-break-after: always\"></div>

| II/0023   | Extension of indication to include monotherapy treatment of adults and adolescent patients aged 12 years and older, with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy for CABOMETYX; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The MAH also took the opportunity to update the local representative for Spain. Version 6.1 of the RMP has also been submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   | 24/03/2022   | 29/04/2022   | SmPC and PL   | Please refer to Scientific Discussion 'Cabometyx-H-C- 004163/II/0023   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|------------------------------------------------------------------------|
| IB/0027   | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 29/12/2021   | n/a          |               |                                                                        |
| IB/0025   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 09/11/2021   | 29/04/2022   | SmPC          |                                                                        |
| IA/0026   | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 19/10/2021   | 29/04/2022   | SmPC          |                                                                        |
| WS/2104   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 02/09/2021   | n/a          |               |                                                                        |

<div style=\"page-break-after: always\"></div>

|         | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                                  |                                                                                                                                                                                                                                                                        |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0024 | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                        | 10/08/2021 | n/a        |                                  |                                                                                                                                                                                                                                                                        |
| IB/0021 | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                         | 25/06/2021 | 29/04/2022 | SmPC and PL                      |                                                                                                                                                                                                                                                                        |
| R/0018  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                           | 25/02/2021 | 21/04/2021 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of CABOMETYX in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity |
| II/0017 | Extension of indication to include in combination with nivolumab first line treatment of advanced renal cell carcinoma for CABOMETYX; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.1 of the RMP has also been submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 25/02/2021 | 26/03/2021 | SmPC and PL                      | Please refer to Scientific Discussion 'Cabometyx-H-C-4163- II-0017'                                                                                                                                                                                                    |
| IB/0020 | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                                                                                                                                                                                                                                                | 26/02/2021 | n/a        |                                  |                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |     | procedure   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| IB/0019   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 26/02/2021 | n/a |             |
| IB/0016/G | This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size | 22/10/2020 | n/a |             |

<div style=\"page-break-after: always\"></div>

|           | AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                        |            |            |                 | and/or limits of an   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------|
| IB/0015/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - | 22/10/2020 | 26/03/2021 | Annex II and PL | Replacement/addition  |

<div style=\"page-break-after: always\"></div>

|         | control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.b.4.z - Change in the batch size (including batch   |            |            |                        |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IA/0014 | B.II.e.1.b.3 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Deletion of an immediate packaging container without a complete deletion of a strength or pharmaceutical form                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 05/06/2020 | 31/07/2020 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0012 Update of section 4.4 of Osteonecrosis as a of the SmPC based on Information: - to add Dysphagia and existing ADR, - to replace neuropathy by Peripheral reflect the broader medical (Deep vein thrombosis) thrombosis in order to frequently reported type Changes to the frequency ADRs are also proposed Additionally, an update align the SmPC of other product is included. The accordingly. The MAH the product Information update the local representative Hungary C.I.4 - Change(s) in the   | 30/04/2020   | 31/07/2020   | SmPC, Labelling and PL   | CABOMETYX (cabozantinib) tablets and COMETRIQ (cabozantinib) capsules are not bioequivalent and should not be used interchangeably. For RCC and HCC, the recommended dose of CABOMETYX is 60 mg once daily. Treatment should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs. Management of suspected adverse drug reactions may require temporary treatment interruption and/or dose reduction of CABOMETYX therapy. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily. Dose interruptions are recommended for management of CTCAE grade 3 or greater toxicities or intolerable grade 2 toxicities. Dose reductions are recommended for events that, if persistent, could become serious or intolerable. If a patient misses a dose, the missed dose should not be taken if it is less than 12 hours before the next dose. Osteonecrosis: Events of osteonecrosis of the jaw (ONJ) have been observed with cabozantinib. An oral examination should be performed prior to initiation of cabozantinib and periodically during cabozantinib therapy. Patients should be advised regarding oral hygiene practice. Cabozantinib treatment should be held at least 28 days prior to scheduled dental surgery or invasive dental procedures, if possible. Caution should be used in patients receiving agents associated with ONJ, such as bisphosphonates. Cabozantinib should be discontinued in patients who experience ONJ. The most common serious adverse drug reactions in the   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                              |            |     | diarrhoea, nausea, hypertension, embolism, hyponatraemia, pulmonary embolism, vomiting, dehydration, fatigue, asthenia, decreased appetite, deep vein thrombosis, dizziness, hypomagnesaemia and palmar- plantar erythrodysaesthesia syndrome (PPES). The most frequent adverse reactions of any grade (experienced by at least 25% of patients) in the RCC population included diarrhoea, fatigue, nausea, decreased appetite, PPES, hypertension, weight decreased, vomiting, dysgeusia, constipation, and AST increased. Hypertension was observed more frequently in the treatment naïve RCC population (67%) compared to RCC patients following prior VEGF-targeted therapy (37%). The most common serious adverse drug reactions in the HCC population (≥1% incidence) are hepatic encephalopathy, asthenia, fatigue, PPES, diarrhoea, hyponatraemia, vomiting, abdominal pain and thrombocytopenia. The most frequent adverse reactions of any grade (experienced by at least 25% of patients) in the HCC population included diarrhoea, decreased appetite, PPES,   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0013 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 06/03/2020 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| N/0010              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                             | 20/12/2019   | 31/07/2020   | PL              |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0011           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                               | 30/10/2019   | 31/07/2020   | SmPC and PL     |                                                                                                                                            |
| IAIN/0009/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 19/08/2019   | 31/07/2020   | Annex II and PL |                                                                                                                                            |
| IA/0008             | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                   | 16/07/2019   | n/a          |                 |                                                                                                                                            |
| PSUSA/10180 /201811 | Periodic Safety Update EU Single assessment - cabozantinib                                                                                                                                                                                                                                                                                                                                   | 27/06/2019   | 27/06/2019   | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10180/201811. |
| IA/0007             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                         | 21/03/2019   | n/a          |                 |                                                                                                                                            |
| II/0005             | Extension of indication to add Cabometyx as monotherapy for the treatment of hepatocellular carcinoma in adults who have previously been                                                                                                                                                                                                                                                     | 20/09/2018   | 12/11/2018   | SmPC and PL     | Please refer to the scientific discussion Cabometyx EMEA/H/C/004163/II/0005.                                                               |

<div style=\"page-break-after: always\"></div>

|                     | treated with sorafenib; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated with safety and efficacy information. The package leaflet and the risk management plan (version 4.2) are updated accordingly. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                            |            |            |                   |                                                                                                                                                      |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10180 /201711 | Periodic Safety Update EU Single assessment - cabozantinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 28/06/2018 | 23/08/2018 | SmPC and PL       | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10180/201711.           |
| II/0003             | Extension of indication to include for the treatment of advanced renal cell carcinoma the 'treatment-naïve adults with intermediate or poor risk' for CABOMETYX; as a consequence, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC are updated. The package Leaflet and risk management plan (version 3.2) are also updated accordingly. In addition, the marketing authorisation holder took the opportunity to make some editorial changes in the product information. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 22/03/2018 | 08/05/2018 | SmPC and PL       | Please refer to Scientific Discussion CABOMETYX - EMEA/H/C/004163/II/0003                                                                            |
| II/0002/G           | This was an application for a group of variations. 1) C.I.4 (type II) Update of section 5.1 of the SmPC to reflect the final                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 09/11/2017 | 08/05/2018 | SmPC and Annex II | Non-clinical and clinical information have been updated in the product information of Cabometyx: The carcinogenic potential of cabozantinib has been |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| study results from clinical study XL184-308: A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy, to fulfil the condition to the marketing authorisation listed as a PAES in the Annex II. The RMP version 2.0 has also been submitted. 2) C.I.4 (type II) Update of section 5.3 of the SmPC to reflect the final study results from non-clinical study XL184-NC-036: 104-Week Oral Gavage Carcinogenicity and Toxicokinetic Study with Cabozantinib (XL184) in Rats. The RMP version 2.0 has also been submitted. 3) C.I.3.z (type IB) Update of section 4.5 of the SmPC to implement the wording agreed by the PRAC following the outcome of the PSUR procedure EMEA/H/C/PSUSA/10180/201603. In addition, the MAH took the opportunity to update the list of local representatives. C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   | evaluated in two species: rasH2 transgenic mice and Sprague-Dawley rats. In the 2-year rat carcinogenicity study XL184-NC-036, cabozantinib-related neoplastic findings consisted of an increased incidence of benign pheochromocytoma, alone or in combination with malignant pheochromocytoma/complex malignant pheochromocytoma of the adrenal medulla in both sexes at exposures well below the intended exposure in humans. The clinical relevance of the observed neoplastic lesions in rats is uncertain. A statistically significant improvement in progression free survival (PFS) was demonstrated for Cabometyx compared to everolimus. A planned interim analysis of overall survival (OS) was conducted at the time of the PFS analysis and did not reach the interim boundary for statistical significance (202 events, HR=0.68 [0.51, 0.90], p=0.006). In a subsequent unplanned interim analysis of OS, a statistically significant improvement was demonstrated for patients randomized to CABOMETYX as compared with everolimus (320 events, median of 21.4 months vs. 16.5 months; HR=0.66 [0.53, 0.83], p=0.0003). Comparable results for OS were observed with a follow-up analysis (descriptive) at 430 events. By submitting the final results of the post-authorisation efficacy study XL184-308 the MAH fulfils the Annex II condition imposed at time of initial marketing authorisation. The information regarding the effect of cabozantinib on other medicinal products is updated to reflect that because of high plasma protein binding levels of cabozantinib a   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     |                                                            |            |     | be possible. In case of such combination, INR values should be monitored.   |
|---------------------|------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------|
| PSUSA/10180 /201611 | Periodic Safety Update EU Single assessment - cabozantinib | 09/06/2017 | n/a | PRAC Recommendation - maintenance                                           |